Navigation Links
Misonix, Inc. To Report Financial Results For The First Quarter Of Fiscal Year 2014 On Thursday, November 7, 2013
Date:11/4/2013

FARMINGDALE, N.Y., Nov. 4, 2013 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, announced today that it will report financial results for the first quarter of fiscal year 2014 ended September 30, 2013 on Thursday, November 7, 2013. The Company has scheduled a conference call that same day, Thursday, November 7, 2013, at 4:30 pm ET to review the results.

Interested parties can access the conference call by dialing (877) 317-6789 or (412) 317-6789 or can listen via a live Internet webcast, which is available in the Investor Relations section of the Company's website at www.misonix.com.

A teleconference replay of the call will be available for three days at (877) 344-7529 or (412) 317-0088, confirmation # 10036674. A webcast replay will be available in the Investor Relations section of the Company's website at www.misonix.com for 30 days.

About MisonixMisonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

Safe Harbor StatementWith the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.Misonix Contact:

Investor Contact: Richard Zaremba

Joe Diaz 631-694-9555 Lytham Partners invest@misonix.com 602-889-9700info@misonix.com


'/>"/>
SOURCE Misonix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Misonix, Inc. Announces Fourth Quarter and Fiscal Year 2013 Financial Results
2. Misonix, Inc. Announces the Grant of Patent by the United States Patent and Trademark Office
3. InspireMD to Report Financial Results for Quarter Ending September 30, 2013 on Monday, November 11, 2013
4. Mast Therapeutics Reports Third Quarter 2013 Financial Results
5. Sinovac to Host Conference Call to Report Third Quarter 2013 Unaudited Financial Results
6. Sellers of Unapproved Drugs Proliferate Online, Posing a Serious Threat to Global Public Health, Reports NABP
7. Four-Star Gen. Barry McCaffrey, Former US Drug Czar, To Report "Drugs In The Workplace -- Understated National Crisis" At Teamsters Health & Benefits Forum Fri., Nov. 8, 10:30 AM At NYC Grand Hyatt
8. Cambrex Reports Third Quarter 2013 Financial Results
9. IRIDEX Reports 2013 Third Quarter Results
10. Surveyed Physicians Report that Invokana Captures a Small Percentage of Patient Share in the Type 2 Diabetes Drug Market, With Significant Increases Expected Six Months from Now
11. Concord Medical to Report Third Quarter 2013 Financial Results on November 12, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 19, 2017 Pfizer joins ... Milner Therapeutics Consortium   Major research ... Cambridge   The Milner Therapeutics ... ) as a partner to the Milner Therapeutics Consortium. ... the efficient transfer of materials between industry and academia ...
(Date:1/19/2017)... , Jan. 18, 2017  ViewRay, Inc. (Nasdaq: ... first and only clinical MRI-guided radiation therapy system, announced ... of approximately $26.1 million through a private placement ... Management led the financing and was joined by ... LLC and Kearny Venture Partners, and an additional ...
(Date:1/19/2017)... 18, 2017 The Academy of Managed ... Administration (FDA) for its release today of draft ... decision makers can proactively share clinical and economic ... as emerging therapies awaiting FDA approval. ... that AMCP developed during two multi-stakeholder meetings last ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... Next week after January 20th, the fear ... political games that circumvent health needs of over 30 million. Many interviews with Dr. ... and needs government public servants were suppose to prioritize. Interviews provided below. ...
(Date:1/19/2017)... ... January 19, 2017 , ... WhoHaha , a digital ... the American Heart Association (AHA) to produce a three-part video series that uses humor ... as part of the launch of AHA’s Healthy For Good™ movement, which is designed ...
(Date:1/19/2017)... ... 19, 2017 , ... Dr. Andrew Lian-Jie Li ... trained Mohs and cosmetic surgeon. After extensive dermatology research training at the National ... in internal medicine at the Emory University and dermatology training at the University ...
(Date:1/19/2017)... Beach, CA (PRWEB) , ... January 19, 2017 ... ... Oral Health, is now offering treatments for patients with sleep apnea and TMJ ... consequences for dental and physical health. Dr. Rassouli provides personalized care to reduce ...
(Date:1/19/2017)... ... January 19, 2017 , ... Rountree Brady Insurance Agency, ... communities throughout eastern Georgia, is embarking on a charity effort to raise awareness ... more Americans every year than anything else, yet risk factors associated with heart ...
Breaking Medicine News(10 mins):